With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older ...

A new study reveals key predictors of successful weight loss on GLP-1RA drugs like Ozempic and Wegovy, including longer ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.